-

Successful Installation of ETH 1.2 GHz NMR System Enables Novel Research Capabilities in Solid-State NMR

ETH Zürich Accepts Bruker 1.2 GHz NMR Spectrometer

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the successful installation and customer acceptance of the Avance™ NEO 1.2 GHz NMR system at the Department of Chemistry and Applied Biosciences of the Eidgenössische Technische Hochschule (ETH) Zürich (www.ethz.ch) in Switzerland. Following the acceptance of the world's first 1.2 GHz NMR at the CERM (www.cerm.unifi.it) of the University of Florence earlier this year, this marks the second customer installation of a 1.2 GHz NMR in the world.

ETH will utilize their new 1.2 GHz NMR system to enable the development of new solid-state NMR techniques, and to apply these techniques to study materials and biological systems, including proteins fibrils which are linked to diseases such as Parkinson’s and Alzheimer’s. The 1.2 GHz spectrometer will also be used as a basis for further improving NMR methodology towards in-cell structural biology, and to investigate solid catalysts and functional materials, e. g. for energy conversion and data storage.

Professors Beat Meier, Matthias Ernst and Alexander Barnes at ETH stated: “We are very excited to have the world’s first 1.2 GHz solid-state NMR spectrometer successfully installed in our lab. The system was delivered just a couple of months ago and the installation and energizing of the NMR magnet went exceptionally well. The completion of the installation marks the culmination of a project that we started with Bruker almost a decade ago. We are very much looking forward to starting our first ultra-high field solid-state NMR experiments.”

Dr. Falko Busse, Bruker BioSpin's Group President, commented: "I am very grateful for the confidence and the trust our partners at ETH have placed in Bruker, and for the outstanding support they gave to our engineers during the installation of the 1.2 GHz NMR. The second successful customer installation of a 1.2 GHz NMR is a testament to the success of our newly developed Ultra-High-Field (UHF) NMR technology. The production of additional UHF systems is well underway. In fact, the installation of the next 1.2 GHz spectrometer will commence at the Max Planck Institute (MPI) in Göttingen, Germany this week. We are thrilled to be able to provide the structural biology and NMR research community with such powerful tools."

Bruker's unique 1.2 GHz NMR magnets utilize a novel hybrid technology with advanced high-temperature superconductors (HTS) in the inner sections, and low-temperature metallic superconductors (LTS) in the outer sections. The Ascend™ 1.2 GHz magnets are stable, homogenous, standard-bore (54 mm) magnets that meet the requirements of high-resolution and solid-state NMR. Bruker's Avance™ NEO 1.2 GHz spectrometers offer different ultra-high field CryoProbes™ for solution-state NMR and fast-spinning MAS solid-state probes.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Investor Contact:
Miroslava Minkova
Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph.D.
VP of Group Marketing
Bruker BioSpin
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Summary
Successful Installation of ETH 1.2 GHz NMR System Enables Novel Research Capabilities in Solid-State NMR
Release Versions

Contacts

Investor Contact:
Investor Contact:
Miroslava Minkova
Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph.D.
VP of Group Marketing
Bruker BioSpin
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com

More News From Bruker Corporation

Bruker Announces Quarterly Preferred Stock Dividend

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR, BRKRP) today announced that its Board of Directors (“Board”) has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company’s 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock Dividend”). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 202...

Bruker Announces Date and Time of Fourth Quarter 2025 Earnings Release and Webcast

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2025 financial results before market opening on Thursday, February 12, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q4 2025 Earnings Webcast” hyperlink in the “Events & Presentat...

Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

HANAU, Germany--(BUSINESS WIRE)--The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration pe...
Back to Newsroom